A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

Immutep ( ($IMMP) ) has shared an announcement. On October 20, 2025, Immutep Limited presented two posters at the ESMO Congress 2025, showcasing ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with ...

Merck (MRK) announced new long-term data highlighting the sustained survival benefits of Keytruda, Merck’s anti-PD-1 therapy, in treating ...

Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...

Data from investigator-initiated Phase II selected for Proffered Paper oral presentation ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics Li ...